

FORMULARY LISTING

A close-up photograph of various pharmaceuticals, including white, yellow, and orange tablets, and red, blue, and gold capsules, scattered on a blue background with faint white text. A purple rectangular box is overlaid on the bottom left of the image.

Formulary and Prescribing Guidelines



EPUT Mental Health & Learning Disabilities Formulary

The Formulary details medicines information on those drugs approved for use within the mental health services of Essex Partnership NHS Foundation Trust, and should be read in conjunction with the Trust's full Formulary and Prescribing Guidelines, containing supporting information to aid in clinical decision making.

Prescribers should always refer to the latest edition of the BNF, BNFc or Summary of Product Characteristics (SmPC) for information regarding dosages, contraindications and side effects. The Formulary is a dynamic document, and is regularly reviewed and updated in view of local drug utilisation work, current evidence-based information, and guidance received from NICE.





Classification of Drugs in the Trust

- The majority of drugs prescribed by prescribers in the Trust will be Formulary drugs, with proven efficacy and supporting evidence.
- Some drugs will require specialist knowledge and are required to be initiated by a Consultant or under his/her direct instructions. These are represented as **shaded amber**.
- Non-Formulary Drugs**, highlighted **bold blue** should not routinely be prescribed. However, they may be made available in exceptional circumstances. Completed Non-Formulary Request Form (CLPGMH-13-Appendix 5) required. E.g. if a patient has been maintained on the drug for some time or if a consultant wishes to try a drug for an individual patient before requesting inclusion in the formulary.
- Where medicines are included in the formulary, they are approved for their licensed indications and may be prescribed in secondary or primary care EXCEPT hospital-only medicines (amber shading)

Please select the Condition you would like to view.

Depression	Psychosis	Bipolar Disorder	Dementia	Anxiety & Insomnia
Substance Misuse	Learning Disability	ADHD	EPSE or Side Effect	Non-Formulary

NB: All drug names are interactive. Hover over specific areas of the document and click if accessible to view the linked information.

Key	
	Non-Formulary Drugs
	Trust Approved Licensed 'alternate' indications
	Trust approved 'off-labelled' indications
	Formulary Drugs

List of Non- Formulary Medicines		List of Medicines Currently Under Review
Agomelatine	Nortriptyline	Cariprazine (MMG minutes December 2019)
Doxepin	Olanzapine Pamoate	Paliperidone 6 monthly Injection (Byanli®)
Esketamine	Orphenadrine	Buprenorphine solution for injection (Buvidal®)
Flurazepam	Tranlycypromine	
Guanfacine	Trimipramine	
Isocarboxazid	Tryptophan	
Lormetazepam	Zaleplon	
Nitrazepam		

Drug	Formulations	Restrictions	Additional Information
Approved Drugs in the treatment of Depression (Adults) Antidepressants Click for Top	See SECTION 1: THE TREATMENT OF DEPRESSION formulary guidelines.		Depression in adults: treatment and management NICE NG222 Depression in children and young people: identification and management NICE NG134 Depression in adults with a chronic physical health problem: recognition and management NICE CG91 Obsessive-Compulsive Disorder (OCD) and Body Dysmorphic Disorder (BDD): treatment NICE CG31 Post-traumatic stress disorder (PTSD) NICE NG116. Generalised Anxiety Disorder (GAD) and Panic Disorder (PD) in adults: management NICE CG113. Social anxiety disorder (SAD): recognition, assessment and treatment. NICE CG159.
	Selective serotonin re-uptake inhibitors		1 st Choice Treatment for Depression ⁱⁱ Baseline ECG to rule out QT Prolongation where required
Citalopram	Tablets: 10mg, 20mg, 40mg		PD Off-Label: depression in children (above age 8 years) and adolescents (2nd line) Off-Label: GAD (2nd line) Off-Label: OCD³ Off-Label: BDD
	Drops: 40mg/ml (1drop=2mg) 4 drops (8 mg) = 10mg tablet		
Escitalopram	Tablets: 5mg, 10mg, 20mg Drops 20mg/ml		PD GAD SAD (alternative 1st line)
Fluoxetine	Tablets: 10 mg		OCD (1st line) depression in children (above age 8 years) (1st line) Off-Label: GAD (2nd line) Off-Label: PD, PTSDⁱⁱⁱ Off-Label: BDD (1st line) Off-Label: OCD and BDD in children (all 1st line) Off-Label: GAD, PD, PTSD, and SAD in children (all 1st choice) Off-Label: Cataplexy in narcolepsy Off-Label: Hyperkinetic disorder / ADHD (adult)
	Dispersible Tablets: 20mg		
	Capsules: 10mg, 20mg, 30mg, 40mg, 60mg		
	Liquid: 20mg/5ml		
Fluvoxamine	Tablets: 50mg, 100mg		Off-Label: SAD (2nd line) Off-Label: Cataplexy in narcolepsy
Paroxetine	Tablets: 10mg, 20mg, 30mg		GAD (2nd line) PD PTSD (1st line) OCD SAD (2nd line) Off-Label: BDD Off-Label: Cataplexy in narcolepsy
Sertraline	Tablets: 50mg, 100mg		PD (1st line) PTSD (1st line) OCD SAD (1st line) Off-Label: depression in children (above age 8 years) and adolescents (2nd line) Off-Label: BDD Off-Label: GAD (1st line)

Drug	Formulations	Restrictions	Additional Information
Serotonin and noradrenaline re-uptake inhibitors			
Duloxetine	Capsules: 20mg, 30mg, 40mg, 60mg		GAD
Venlafaxine	Tablets: 37.5mg, 75mg		Off-Label: PTSD (1 st line)
	M/R Capsule: 37.5mg, 75mg, 150mg		GAD (2 nd line) SAD (2 nd line)
	M/R Tablets: 37.5mg, 75mg, 150mg, 225mg		
Tricyclic & related antidepressant Medicines (TCAs)			Increased risk of fatality in overdose ² . Off-Label: Hyperkinetic disorder / ADHD (adult)
Amitriptyline	Tablets: 10mg, 25mg, 50mg		Off-Label: PTSD ^{III}
	Liquid: 50mg/5ml		
Clomipramine	Capsules: 10mg, 25mg, 50mg		OCD Off-Label: GAD, PD, BDD
Dosulepin	Capsules: 25mg	For existing patients only, if no contraindication. Do not switch or start dosulepin.	
	Tablets: 75mg		
Imipramine	Tablets: 10mg, 25mg		Off-Label: PD, PTSD ^{III}
	Liquid: 25mg/5ml		
Lofepramine	Tablets: 70mg		
	Liquid: 70mg/5ml		
Trazodone	Capsules: 50mg, 100mg		Off-Label: Behavioural & Psychological Symptoms of Dementia Off-Label: Insomnia
	Tablets: 150mg		
	Liquid: 50mg/5ml		
Monoamine – oxidase inhibitors (MAOIs)			Specialist Initiation Advised due to safety concerns.
Moclobemide	Tablets: 150mg, 300mg		SAD (3 rd line)
Phenelzine	Tablets: 15mg		Off-Label: PTSD ^{III} Off-Label: SAD (alternative 3 rd line)
Other			
Mirtazapine	Tablets: 15mg, 30mg, 45mg		Off-Label: PTSD ^{III}
	Orodispersible Tablets: 15mg, 30mg, 45mg		
	Liquid: 15mg/ml		
Vortioxetine	Tablets: 5mg, 10mg, 20mg	3 rd line for depression	NICE TA367
Approved Drugs in the treatment of Psychosis Antipsychotic Drugs <			

Drug	Formulations	Restrictions	Additional Information
Haloperidol	Tablets: 1.5mg, 5mg, 10mg Liquid: 2mg/ml, 5mg/5ml Injection: 5mg/ml		Delirium (as per SECTION 11: DRUG USE IN OLDER ADULTS formulary guidelines) Treatment of persistent aggression, psychotic symptoms in patients with moderate to severe Alzheimer's dementia. (BPSD). Off-Label: OCD^{III} (as augmentation)
Sulpiride	Tablets: 200mg, 400mg Liquid: 200mg/5ml		
Trifluoperazine	Tablets: 1mg, 5mg Liquid: 1mg/5ml, 5mg/5ml		
Zuclopenthixol Dihydrochloride	Tablets: 2mg, 10mg, 25mg		
Zuclopenthixol acetate (Acuphase)	Injection: 50mg/mL	Max. cumulative dose 400 mg over 2 weeks and 4 injections.	Should not be confused with depot preparations (i.e. zuclopenthixol <i>decanoate</i>) – see BNF for detailed safety information.
Atypical Antipsychotics (Second Generation Antipsychotics (SGA))			SGAs highlighted in bold are associated with lower acquisition costs. If more than one SGA is appropriate for a particular service user, one with a low acquisition cost should be prescribed to ensure cost effectiveness within the health economy. <i>Depression in adults: recognition and management [NICE CG90]</i> <i>NICE Clinical guideline [CG185]: Antipsychotic use in Bipolar Disorder</i>
Amisulpride	Tablets: 50mg, 100mg, 200mg, 400mg Liquid: 100mg/ml		
Aripiprazole	Tablets: 5mg, 10mg, 15mg, 30mg Orodispersible Tablets: 10 mg, 15 mg Oral Solution: 1mg/ml Injection: 7.5mg/ml (immediate release)		Mania and hypomania in adolescents aged 13 and older (for up to 12 weeks) Schizophrenia in adolescents (aged 15 years and older) (1st choice) Off-Label: BPSD
Cariprazine	Tablets: 1.5 mg, 3 mg, 4.5 mg, 6 mg	Non-formulary request form required. Prescribing not to be passed to GP.	Female patients of child-bearing potential must use highly effective contraceptive methods during treatment and for at least 10 weeks following the last dose.
Clozapine	Tablets: 25mg, 100mg	Clozaril® utilised by Trust, along with <i>Clozaril Patient Monitoring Service</i> (CPMS).	Psychosis during the course of Parkinson's disease. Off-Label: BPAD rapid cycling
	Injection: 125mg/5ml		Unlicensed Product. To be used in line with Trust Guidance.
Lurasidone	Tablets: 18.5mg, 37mg, 84mg	3 rd line once other atypical antipsychotics (incl. aripiprazole) have been considered	
Olanzapine	Tablets: 2.5mg, 5mg, 7.5mg, 10mg, 15mg, 20mg		Mania. Off-Label: bipolar depression Off-Label: psychosis in children and adolescents Off-Label: PTSD^{III}, OCD^{III} (Augmentation of antidepressant) Off-Label: Anorexia Off-Label: BPSD
	Orodispersible Tablets: 5mg, 10mg, 15mg, 20mg		
	Injection: 5 mg/mL (non-depot)	Imported product	No licensed product available in the UK. Has to be imported from EU.
Quetiapine	Tablets: 25mg, 100mg, 150mg, 200mg, 300mg		Bipolar disorder (BAD) Off-Label: OCD^{III} (as augmentation) Off-Label: BPSD
	Modified Release Tablets: 50mg, 200mg, 300mg, 400mg		

Drug	Formulations	Restrictions	Additional Information
Risperidone	Tablets: 0.25mg, 0.5mg, 1mg, 2mg, 3mg, 4mg, 6mg		Mania persistent aggression in patients with moderate to severe Alzheimer's dementia (up to 6 weeks) persistent aggression in conduct disorder in children from the age of 5 years with sub-average intellectual functioning (up to 6 weeks) Off-Label: psychosis in children and adolescents Off-Label: PTSD^{NICE&III} Off-Label: OCD^{III} (as augmentation) Off-Label: Hyperkinetic disorder / ADHD (adult)
	Liquid: 1mg/ml		
	Orodispersible Tablets: 0.5mg, 1mg, 2mg, 3mg, 4mg		
Depot Injections			
Aripiprazole	Abilify Maintena® (Long acting) Injection: 400mg	Requires consultant to complete the SGA Depot Initiation Form from Appendix 8 of SECTION 2: TREATMENT OF PSYCHOSIS formulary guidelines.	Off-Label: Bipolar Affective Disorder (all depot forms of antipsychotics licensed in their oral form for the treatment of bipolar disorder can be used in their depot form for this indication as well as per Introduction to formulary guidelines)
Flupentixol Decanoate	Injection: 20mg/ml, 40mg/2ml, 50mg/0.5ml, 100mg/ml, 200mg/ml		
Haloperidol Decanoate	Injection: 50mg/ml, 100mg/ml		
Olanzapine Pamoate Monohydrate	Injection: 210mg, 300mg, 405mg	Requires consultant to complete the SGA Depot Initiation Form from Appendix 10 of SECTION 2: TREATMENT OF PSYCHOSIS formulary guidelines.	Subject to MMG Approval. Named Patient Request Form Required (see column to the left).
Paliperidone Palmitate	Xeplion® (monthly) Injection: 50mg, 100mg, 150mg PFS	Requires consultant to complete the SGA Depot Initiation Form from Appendix 8 of SECTION 2: TREATMENT OF PSYCHOSIS formulary guidelines.	
	Trevicta® (3 monthly) Injection: 175mg, 263mg, 350mg, 525mg		
Risperidone	Risperdal Consta® (Long-acting) Injection: 25mg, 37.5mg, 50mg	Requires consultant to complete the SGA Depot Initiation Form from Appendix 8 of SECTION 2: TREATMENT OF PSYCHOSIS formulary guidelines.	Off-Label: Bipolar Affective Disorder
Zuclopenthixol Decanoate	Injection: 200mg/ml, 500mg/ml		
Approved Drugs for the management of Bipolar Affective Disorder (BAD). Click for Top		See SECTION 3: MANAGEMENT OF BIPOLAR AFFECTIVE DISORDER formulary guidelines.	<i>NICE Clinical guideline [CG185]</i> Antipsychotic monitoring required as per appendices 1, 2, 4, and 5 of SECTION 2: TREATMENT OF PSYCHOSIS formulary guidelines. Mood stabiliser monitoring required as per appendix 1 of SECTION 3: MANAGEMENT OF BIPOLAR AFFECTIVE DISORDER formulary guidelines.
Mood stabilisers			
See Anti-Epileptic Medication			
See SGA Antipsychotic Medication			
Asenapine	Sublingual Tablets 5mg, 10mg	Needs to be initiated and prescribed by a consultant on an ongoing basis.	

Drug	Formulations		Restrictions	Additional Information
Lithium Carbonate (tablets)	Priadel® Modified Release Tablets: 200mg, 400mg (scored)			See <u>Lithium Shared Care Protocol</u> Priadel® to be used for any new patients Other brands are for continuation only
	Camcolit®- Controlled Release Tablets 400mg (scored)			
	Essential Pharma 250mg Tablets (Bioequivalent to Camcolit - rebranded)			
	Liskonium® 450mg Tablets			
Lithium Citrate (liquids)	Li-liquid®	Yellow liquid: 509mg/5ml (<i>200mg of Lithium Tablet</i>) Orange Liquid: 1.018g/5ml (<i>400mg of Lithium Tablet</i>)	Brand Specific Prescribing required.	See <u>Lithium Shared Care Protocol</u>
	Priadel® Liquid: 520mg/5ml (204mg of Lithium Tablet)			
Valproic Acid as Semi-sodium Valproate	Depakote® Tablets: 250mg, 500mg		Contraindicated in women of childbearing potential unless they meet the conditions of the <i>Pregnancy Prevention Programme</i> ¹ .	
For EPUT use only, not to be initiated or continued by primary care prescribers: <u>Omega-3 acid ethyl esters</u> . Some evidence for improvement in bipolar disorder. Advise patient to purchase if possible. Review concordance.				
Approved Drugs for Use as Anxiolytics in ADULTS. Click for Top			See <u>SECTION 4: TREATMENT OF ANXIETY</u> formulary guidelines.	<i>Obsessive-compulsive Disorder (O.C.D.) and Body Dysmorphic Disorder (B.D.D.): treatment NICE CG31.</i> <i>Post-traumatic stress disorder NICE NG116.</i> <i>Generalised Anxiety Disorder (GAD) and Panic Disorder (PD) in adults: management NICE CG113.</i>
Anxiolytics				
See Antidepressants - SSRIs				1 st and 2 nd choice for GAD and PD
See Antidepressants - SNRIs				Venlafaxine is 2 nd choice for GAD.
See Antidepressants - TCAs (i.e. amitriptyline, clomipramine, imipramine, trazodone)				Off-Label: GAD, PD, BDD
See Anti-Epileptic Medication (i.e. pregabalin)				Pregabalin is 3 rd choice for GAD.
See Sedating Antihistamines (i.e. promethazine)				Off-label promethazine is approved for use in GAD.
Buspirone	Tablets: 5mg, 10mg			Treatment of short-term management of anxiety disorders and the relief of symptoms of anxiety with or without accompanying symptoms of depression. (Approved for GAD in formulary guidelines). Off-Label: BDD.
Hydroxyzine	Tablets: 10mg, 25mg			Symptomatic treatment of anxiety in adults. (Approved for GAD in formulary guidelines).
Lorazepam	Tablets: 1 mg, 2.5 mg		Controlled Drug [CD 4-1]	Symptomatic relief of anxiety that is severe, disabling or subjecting the individual to unacceptable distress. (Approved for GAD in formulary guidelines). Off-Label: BPSD Off-Label: acute psychosis / agitation / mania. Off-Label: alcohol withdrawal in patients with liver impairment
	Injection: 4mg/ml			

¹ See details at <https://www.gov.uk/drug-safety-update/valproate-pregnancy-prevention-programme-actions-required-now-from-gps-specialists-and-dispensers>.

Drug	Formulations	Restrictions	Additional Information
Diazepam	Tablets: 2mg, 5mg, 10mg	Controlled Drug [CD 4-1]	Short-term relief (2-4 weeks only) of severe/distressing anxiety. (Approved for GAD in formulary guidelines). Off-Label: acute psychosis / agitation / mania Off-Label: benzodiazepine withdrawal
	Liquid: 2mg/5ml, 5mg/5ml		
	Injection: 10mg/2ml		
	Enema: 2mg/ml, 4mg/ml		
Propranolol	Tablets: 10mg, 40mg, 80mg		Relief of situational anxiety and generalised anxiety symptoms, particularly those of somatic type. (Approved for GAD in formulary guidelines). Off-Label: agitation / aggression in brain injury Off-Label: antipsychotic induced akathisia
	Liquid: 5mg/5ml, 10mg/5ml, 50mg/5ml		
Approved Drugs for the treatment of Short term Insomnia in ADULTS. Hypnotics		See SECTION 5: TREATMENT OF INSOMNIA formulary guidelines.	
Hypnotics		NICE TA77 advises that "given the lack of compelling evidence on any clinically differences between the Z-drugs and the shorter-acting benzodiazepine hypnotics" (i.e. loperazolam, lormetazepam, and temazepam), "unless a patient experiences adverse effects considered to be directly related to a specific hypnotic, the drug with the lowest purchase cost should be used in preference to more expensive alternatives".	
Melatonin	Modified Release Tablets: (Circadin®) 2mg	Circadin® is subject to a 'Non-Formulary' request approval.	Circadin® is licensed as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over. Circadin® is the only licensed version in the UK. All other preparations as 'Specials'.
Temazepam	Tablets: 10mg, 20mg	Controlled Drug [CD 3]	Short term treatment of insomnia (2 nd line)
	Liquid: 10mg/5ml		
Zopiclone	Tablets: 3.75mg, 7.5mg	Controlled Drug [CD 4-1]	Short term treatment of insomnia (1 st line)
Zolpidem	Tablets: 5mg, 10mg	Controlled Drug [CD 4-1]	Short term treatment of insomnia (alternative 1 st line)
Sedating Antihistamines			
Promethazine	Tablets: 10mg, 25mg		Short term treatment of insomnia (3 rd line) Off-Label: GAD Off-Label: acute agitation Off-Label: acute anxiety² (no Published evidence) Off-Label: aggression in brain injury Off-Label: borderline personality disorder (crisis) – short Term Use
	Injection: 25mg/ml		
	Liquid: 5mg/5ml		
Approved drugs for the Treatment of ADHD. Stimulants		See SECTION 6: TREATMENT OF ADHD formulary guidelines.	Attention deficit hyperactivity disorder: diagnosis and management [NICE NG87]
Click for Top			
Central Nervous System Stimulants			
Atomoxetine	Capsules: 10mg, 18mg, 25mg, 40mg, 60mg, 80mg, 100mg	3 rd line in children and adults (who cannot tolerate lisdexamfetamine and methylphenidate).	ADHD in children (age 6 years and older). See Shared Care Protocol For ADHD .
	Liquid: 4mg/ml		

Drug	Formulations	Restrictions	Additional Information
Dexamfetamine	Tablets: 5mg, 10mg, 20mg	2 nd and 3 rd line in adults and children (after methylphenidate and lisdexamfetamine), respectively. Controlled Drug [CD 2]	ADHD in children and adolescents (age 6 to 17 years). See Shared Care Protocol For ADHD .
	Modified Release Tablets: 5mg, 10mg, 15mg		
	Liquid: 5mg/5ml		
Lisdexamfetamine	Capsules: 20mg, 30mg, 40mg, 50mg, 60mg, 70mg	1 st and 2 nd line in adults and children (after methylphenidate), respectively. Controlled Drug [CD 2]	ADHD in children aged 6 and over when response to previous methylphenidate is considered clinically inadequate. Off-Label: ADHD in children aged 5 years (2nd line) See Shared Care Protocol For ADHD .
Methylphenidate	Tablets: 5mg, 10mg, 20mg	1 st choice (for both adults and children above 5 years of age) Controlled Drug [CD 2]	ADHD in children of 6 years of age and over. Off-Label: ADHD in children aged 5 years (1st line) See Shared Care Protocol For ADHD .
	M/R Tablets: 18mg, , 27mg, 36mg, 54mg		
	M/R Capsules: 5mg, 10mg, 20mg, 30mg, 40mg, 50mg, 60mg		
Other			See <i>fluoxetine (above)</i>
Clonidine	Tablets: 25micrograms, 100micrograms	Do not offer to children with ADHD and sleep disturbance, rages or tics, except on advice of tertiary ADHD service.	Off-Label: antipsychotic induced akathisia Off-Label: hyperkinetic disorder / ADHD (adult) Off-Label: opiate withdrawal Off-Label: refractory PTSD Off-Label: tics
	Liquid: 50micrograms/5ml		
Guanfacine	modified release tablets: 1 mg, 2 mg, 3 mg	3 rd choice for children aged 5 years and over if they cannot tolerate methylphenidate or lisdexamfetamine. Do not offer to adults, except on advice of tertiary ADHD service.	ADHD in children and adolescents (6-17 years) for whom stimulants are not suitable, not tolerated or have been shown to be ineffective.
Approved Drugs for the Management of Dementia		See SECTION 7: MANAGEMENT OF DEMENTIA formulary guidelines.	Dementia: assessment, management and support for people living with dementia and their carers [NICE NG97] Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer's disease [NICE TA217] Parkinson's disease in Adults [NICE NG71]
Click for Top			
See Antipsychotics – 1 st & 2 nd Generation			see indication BPSD above
Donepezil	Tablets: 5 mg, 10 mg	Mild to moderate dementia in Alzheimer's disease.	See Shared Care Protocol for Dementia . Off-Label: mild to moderate or severe dementia with Lewy bodies (1st line) Off-Label: vascular dementia (only in suspected comorbid Alzheimer's disease, Parkinson's disease, or dementia with Lewy bodies) Off-Label: Parkinson's disease dementia (1st line)
	Tablets 5 mg, 10 mg, Orodispersible Tablets: 5mg, 10mg		
Galantamine	Tablets: 8mg, 12mg	Mild to moderate dementia in Alzheimer's disease.	See Shared Care Protocol for Dementia . Off-Label: mild to moderate dementia with Lewy bodies (2nd line) Off-Label: vascular dementia (only in suspected comorbid Alzheimer's disease, Parkinson's disease, or dementia with Lewy bodies) Off-Label: Parkinson's disease dementia (1st line)
	Oral Solution: 4mg/mL		
	M/R Capsules: 8mg, 16mg, 24mg		
Rivastigmine	Capsules: 1.5mg, 3mg, 4.5mg, 6mg	Mild to moderate dementia in Alzheimer's disease.	Mild to moderately severe dementia in patients with idiopathic Parkinson's disease (capsules only). See Shared Care Protocol for Dementia . Off-Label: mild to moderate dementia or severe with Lewy bodies (1st line)
	Oral Solution: 2mg/mL.		
	Patches: 4.6mg/24hours; 9.5mg/24hours, 13.3mg/24 hours		

Drug	Formulations	Restrictions	Additional Information
			Off-Label: vascular dementia (only in suspected comorbid Alzheimer's disease, Parkinson's disease, or dementia with Lewy bodies)
Memantine	Tablets: 5mg, 10mg, 20mg	Moderate to severe dementia in Alzheimer's disease.	See Shared Care Protocol for Dementia . Off-Label: dementia with Lewy bodies (2 nd line) Off-Label: vascular dementia (only in suspected comorbid Alzheimer's disease, Parkinson's disease, or dementia with Lewy bodies) Off-Label: Parkinson's disease dementia (2 nd line)
	Soluble Tablets: 10mg, 20mg		
	Oral Solution: 5mg/actuation (10mg/ml)		
Approved Drugs for the Management of Movement Disorders and Extrapyrimal Side Effects Click for Top		See SECTION 9: MANAGEMENT OF MOVEMENT DISORDER AND EXTRAPYRAMIDAL SIDE EFFECTS formulary guidelines.	The use of benzodiazepines is approved for antipsychotic induced akathisia (off-label).
Anticholinergics			
Atropine	Eye Drops: 1%		Off-Label: clozapine-induced hypersalivation ²
Hyoscine Hydrobromide	Tablets: 150micrograms, 300micrograms		Off-Label: clozapine-induced hypersalivation ² Sublingual use Off-Label.
	Chewable Tablet: 150 microgram, 300 microgram		
	Injections: 400mg/ml, 600mg/ml		
	Patch: 1.5mg		
Pirenzepine	Tablet: 50mg	No licensed product available in the UK and needs to be imported.	Off-Label: clozapine-induced hypersalivation ²
Procyclidine	Injection: 5mg/mL		
	Tablet: 5mg		
	Liquid: 5mg/5mL		
Trihexyphenidyl	Tablets: 2mg, 5mg		Off-Label: clozapine-induced hypersalivation ²
	Liquid: 5mg/5mL		
Approved Drugs Used for Psychotropic-Induced Side Effects			
Other			
Amantadine	Capsule: 100mg Liquid: 50mg/5ml		Off-Label: antipsychotic-induced hyperprolactinaemia
Bromocriptine	Tablet: 2.5mg		Off-Label: antipsychotic-induced hyperprolactinaemia
Cyproheptadine	Tablet: 4mg		Off-Label: antipsychotic-induced akathisia Off-Label: SSRI-Induced Sexual Dysfunction
Fludrocortisone	Tablet: 100micrograms		Off-Label: antipsychotic-induced hypotension
Tetrabenazine	Tablet: 25mg		Off-Label: antipsychotic-induced tardive dyskinesia
Approved drugs for the management of alcohol dependence (detoxification or abstinence)		See SECTION 10: MANAGEMENT OF ALCOHOL, OPIOID AND BENZODIAZEPINE DEPENDENCE formulary guidelines.	Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence [NICE CG115] Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings [NICE CG120]

Drug	Formulations	Restrictions	Additional Information
Click for Top			<p><i>Drug misuse in over 16s: opioid detoxification [NICE CG52]</i></p> <p><i>Coexisting severe mental illness and substance misuse: community health and social care services [NICE NG58]</i></p> <p><i>Drug misuse prevention: targeted interventions [NICE NG64]</i></p>
Alcohol Dependence			
Acamprosate	Tablet: 333mg		
Disulfiram	Tablet: 200mg		
Naltrexone	Tablet: 50mg		Off-Label: aggressive/impulsive behaviour
Nalmefene	Tablet: 18mg	Licensed for the reduction of alcohol consumption in adult patients with alcohol dependence who do not require immediate detoxification.	
Vitamins			
Pabrinex Intramuscular High Potency Injection and Pabrinex Intravenous High Potency, Concentrate for Solution for Infusion	Injections: 2ml, 5ml	Licensed for the rapid therapy of severe depletion or malabsorption of the water soluble vitamins B and C, particularly in alcoholism, where a severe depletion of thiamine can lead to Wernicke's encephalopathy.	
Thiamine	Tablets: 50mg, 100mg		
Vitamin B Compound Strong	Tablets		
Benzodiazepines			see lorazepam above
Chlordiazepoxide	Capsules: 5mg, 10mg		Licensed for symptomatic relief of acute alcohol withdrawal.
Oxazepam	Tablets: 10mg, 15mg		Off-Label: alcohol withdrawal in patients with liver impairment
Opioid Dependence			<p>Consult Local CDAS.</p> <p>See SECTION 10: MANAGEMENT OF ALCOHOL, OPIOID AND BENZODIAZEPINE DEPENDENCE formulary guidelines.</p>
Methadone	Solutions: 1mg/ml Sugar Free. 1mg/ml (with sucrose)	Controlled Drug [CD 2]	
	Tablets: 5mg		
	Capsules: 5mg (unlicensed product)		
Buprenorphine	S/L Tablets: 0.4mg, 2mg, 8mg	Controlled Drug [CD 3]	The tablets should be kept under the tongue until dissolved (usually within 5 to 10 minutes).
	Oral Lyophilisate (Espranor®) 2mg, 8mg (<i>not</i> bioequivalent to the buprenorphine forms above)	Controlled Drug [CD 3]	The administration is oromucosal and the tablet is placed <i>on the tongue</i> (not under it). The tablet usually disperses within 15 seconds.
Buprenorphine + Naloxone (Suboxone)	S/L Tablets: (2mg + 0.5mg), (8mg + 2mg)	Controlled Drug [CD 3]	Film is to be placed under the tongue or inside either cheek until completely dissolved.
Naloxone	Injection: 1mg/ml (Prenoxad®)	Prenoxad® and Nyxoid® for use by CDAS staff for administration and supply to service users/carers under the <i>Naloxone Take Home Programme</i> .	management of opioid overdose
	Nasal spray: 1.8mg (Nyxoid®)		

Drug	Formulations	Restrictions	Additional Information
Approved Drugs Used in Learning Disabilities.		See SECTION 13: DRUG USE IN LEARNING DISABILITIES formulary guidelines.	<i>Epilepsies: Diagnosis and Management.</i> <i>Cannabis-based medicinal products. [NICE CG 137]</i> <i>Cannabis-based medicinal products. [NICE guideline NG144]</i>
Click for Top			
Anti - Epileptic Drugs			
Carbamazepine	Tablets: 100mg, 200mg, 400mg.		Prophylaxis of BAD (in patients unresponsive to other drugs). (The indication in the SPC refers to patients unresponsive to lithium). Off-Label: agitation / aggression in brain injury Off-Label: Aggressive/impulsive behaviour Off-Label: BPSD Controlled release preparations should be prescribed when possible.
	M/R Tablets: (scored), 200mg, 400mg.		
	Liquid: 100mg/5mL		
	Suppository: 125mg (=100mg tab), 250mg		
Clobazam	Tablet: 10mg		
	Suspensions: 5mg/5ml, 10mg/5ml		
Clonazepam	Tablets: 0.5mg, 1mg, 2mg Oral drops 2.5mg/ml		Off-Label: acute psychosis / agitation / mania. Off-Label: BPAD rapid cycling
	Liquid: 500microgram/5ml, 2mg/5ml		
	Oral Lyophilisate: 500 micrograms		
Ethosuximide	Capsule: 250mg		
	Liquid: 250mg/5ml		
Gabapentin	Capsules: 100mg, 300mg, 400mg	Controlled Drug [CD 3]	Off-Label: Bipolar affective disorder
	Tablets: 600mg, 800mg		
	Liquid: 50mg/ml		
Lacosamide	Tablets: 50mg, 100mg, 150mg, 200mg		
	Liquid: 10mg/ml		
Lamotrigine	Tablets: 25mg, 50mg, 100mg, 200mg	Do not offer lamotrigine to treat mania.	Bipolar depression Off-Label: Refractory schizophrenia Off-Label: BPAD rapid cycling
	Dispersible Tablets: 2mg, 5mg, 25mg, 100mg		
Levetiracetam	Tablets: 250mg, 500mg, 750mg, 1g.		
	Liquid: 100mg/ml		
Midazolam	Oromucosal Solution: 10mg/2ml	Controlled Drug [CD 3]	Off-Label: acute psychosis / agitation / mania.
	Injection: 1mg/ml, 2 mg/ml, 5mg/ml		
Oxcarbazepine	Tablets: 150mg, 300mg, 600mg		
	Suspension S/F: 60mg/ml		
Phenobarbital	Tablets: 15mg, 30mg, 60mg	Controlled Drug [CD 3]	
	Liquid: 15mg/5ml		
Phenytoin	Tablet: 100 mg.		
	Capsules: 25mg, 50mg, 100mg, 300mg.		
	Oral suspension: 30mg/5mL		
Pregabalin	Capsules: 25mg 50mg 75mg, 100mg, 150mg, 200mg, 225mg, 300mg	Controlled Drug [CD 3]	GAD (3rd line, if SSRIs/SNRIs ineffective/not tolerated)
	Liquid: 20mg/ml		
Primidone	Tablets: 50mg, 250mg		
	Liquid: 25mg/ml		
Tiagabine	Tablets: 5mg, 10mg, 15mg		
Topiramate	Tablets: 25mg, 50mg, 100mg, 200mg		
	Sprinkle Capsules: 15mg, 25mg, 50mg		

Drug	Formulations	Restrictions	Additional Information
Sodium Valproate	Tablet (crushable): 100mg.	Contraindicated in women of childbearing potential unless they meet the conditions of the <i>Pregnancy Prevention Programme</i> .	<p>Licensed for the treatment of epilepsy.</p> <p>Off-Label: treatment of mania/hypomania (3rd line after an antipsychotic and lithium)</p> <p>Off-Label: prophylaxis of episodes in BAD (2nd line)</p> <p>Off-Label: agitation / aggression in brain injury</p> <p>Off-Label: aggressive/impulsive behaviour</p> <p>Off-Label: BPSD</p>
	Tablets E/C: 200mg, 500mg		
	Capsules M/R: 150 mg, 300 mg		
	Liquid: 200mg/5mL.		
	Granules M/R: 50mg, 100mg 250mg, 500mg, 750mg, 1000mg.		
	Tablets M/R: 200mg, 300mg, 500mg		
Vigabatrin	Tablet: 500mg		
	Powder: 500mg/sachet		
Zonisamide	Capsules: 25mg, 50mg, 100mg		

References

- Electronic Medicines Compendium [EMC]. (2020). Available from <https://www.medicines.org.uk/emc> [Accessed June 10, 2021]
- The Maudsley Prescribing Guidelines 13th Edition (2018); Taylor, Barnes & Young; Wiley Blackwell.
- Baldwin, D.S., et al (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. [Online] Available from https://www.bap.org.uk/pdfs/BAP_Guidelines-Anxiety.pdf [Accessed August 25, 2021]
- National Institute of Health and Care Excellence [NICE]. (2004). Guidance on the use of zaleplon, zolpidem and zopiclone for the short-term management of insomnia [NICE TA77]. [Online] Available from <https://www.nice.org.uk/guidance/ta77/chapter/1-Guidance> [Accessed October 6, 2021]
- National Institute of Health and Care Excellence [NICE]. (2005). Obsessive-Compulsive Disorder (**OCD**) and Body Dysmorphic Disorder (**BDD**): treatment [NICE CG31]. [Online] Available from <https://www.nice.org.uk/guidance/cg31/chapter/1-Guidance> [Accessed September 14, 2021]
- National Institute of Health and Care Excellence [NICE]. (2007). Drug misuse in over 16s: opioid detoxification [NICE CG52]. [Online] Available from <https://www.nice.org.uk/guidance/cg52/chapter/1-Guidance> [Accessed October 6, 2021]
- National Institute of Health and Care Excellence [NICE]. (2009a). Depression in adults: recognition and management [NICE CG90]. [Online] Available from <https://www.nice.org.uk/guidance/cg90/chapter/Recommendations> [Accessed September 14, 2021]
- National Institute of Health and Care Excellence [NICE]. (2009b). Depression in adults with a chronic physical health problem: recognition and management [NICE CG91]. [Online] Available from <https://www.nice.org.uk/guidance/cg91/chapter/Recommendations> [Accessed September 14, 2021]
- National Institute of Health and Care Excellence [NICE]. (2011a). Alcohol-use disorders: diagnosis, assessment and management of harmful drinking (high-risk drinking) and alcohol dependence [NICE CG115]. [Online] Available from <https://www.nice.org.uk/guidance/cg115/chapter/1-Guidance> [Accessed October 6, 2021]
- National Institute of Health and Care Excellence [NICE]. (2011b). Coexisting severe mental illness (psychosis) and substance misuse: assessment and management in healthcare settings [NICE CG120]. [Online] Available from <https://www.nice.org.uk/guidance/cg120/chapter/1-Guidance> [Accessed October 6, 2021]
- National Institute of Health and Care Excellence [NICE]. (2013). Social anxiety disorder (**SAD**): recognition, assessment and treatment. [NICE CG159]. [Online] Available from <https://www.nice.org.uk/guidance/cg159/chapter/1-Recommendations#interventions-for-adults-with-social-anxiety-disorder-2> [Accessed September 14, 2021]
- National Institute of Health and Care Excellence [NICE]. (2014). Psychosis and schizophrenia in adults: prevention and management [NICE CG178]. Available from <https://www.nice.org.uk/guidance/cg178/chapter/1-recommendations>. [Accessed September 23, 2021]
- National Institute of Health and Care Excellence [NICE]. (2016). Coexisting severe mental illness and substance misuse: community health and social care services [NICE NG58]. [Online] Available from <https://www.nice.org.uk/guidance/ng58/chapter/Recommendations> [Accessed October 6, 2021]

14. National Institute of Health and Care Excellence [NICE]. (2017). Drug misuse prevention: targeted interventions [NICE NG64]. [Online] Available from <https://www.nice.org.uk/guidance/ng64/chapter/Recommendations>. [Accessed October 6, 2021]
15. National Institute of Health and Care Excellence [NICE]. (2018a). Dementia: assessment, management and support for people living with dementia and their carers [NICE NG97]. [Online] Available from <https://www.nice.org.uk/guidance/ng97/chapter/Recommendations#pharmacological-interventions-for-dementia>. [Accessed September 23, 2021]
16. National Institute of Health and Care Excellence [NICE]. (2018b). Post-traumatic stress disorder (PTSD) [NICE NG116]. [Online] Available from <https://www.nice.org.uk/guidance/ng116/chapter/Recommendations#management-of-ptsd-in-children-young-people-and-adults> [Accessed September 14, 2021]
17. National Institute of Health and Care Excellence [NICE]. (2018c). Donepezil, Galantamine, Rivastigmine and Memantine for the treatment of Alzheimer's disease [NICE TA217]. [Online] Available from <https://www.nice.org.uk/guidance/ta217/chapter/1-Guidance> [Accessed October 3, 2021]
18. National Institute of Health and Care Excellence [NICE]. (2019a). Depression in children and young people: identification and management [NICE NG134]. [Online] Available from <https://www.nice.org.uk/guidance/ng134/chapter/Recommendations#step-3-managing-mild-depression> [Accessed September 14, 2021]
19. National Institute of Health and Care Excellence [NICE]. (2019b). Generalised Anxiety Disorder (**GAD**) and Panic Disorder (**PD**) in adults: management [NICE CG113]. [Online] Available from <https://www.nice.org.uk/guidance/cg113/ifp/chapter/What-treatments-should-I-be-offered-for-GAD>. [Accessed September 14, 2021]
20. National Institute of Health and Care Excellence [NICE]. (2019c). Attention deficit hyperactivity disorder: diagnosis and management [NICE NG87]. [Online] Available from <https://www.nice.org.uk/guidance/ng87/chapter/Recommendations> [Accessed October 3, 2021]
21. National Institute of Health and Care Excellence [NICE]. (2020). Bipolar disorder: assessment and management [NICE CG185]. [Online] Available from <https://www.nice.org.uk/guidance/cg185/chapter/1-Recommendations> [Accessed September 17, 2021]
22. National Institute of Health and Care Excellence [NICE]. (2021a). Epilepsies: Diagnosis and Management [NICE CG 137] [Online] Available from <https://www.nice.org.uk/guidance/cg137/chapter/1-Guidance>. [Accessed October 17, 2021].
23. National Institute of Health and Care Excellence [NICE]. (2021b). Cannabis-based medicinal products. [NICE NG144]. [Online] Available from <https://www.nice.org.uk/guidance/ng144/chapter/Recommendations>. [Accessed October 17, 2021]